secwatch.observer — SEC 8-K summary
======================================

Issuer:     bluebird bio, Inc. (—)
CIK:        0001293971
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001293971-24-000020
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bluebird bio Q1 net revenue $18.6M; 15 patient starts year-to-date; restates prior financials
--------------------------------------------------------------------------------

- Q1 2024 net revenue $18.6M vs $2.4M Q1 2023, driven by ZYNTEGLO revenue increase.
- 15 patient starts in 2024: 11 ZYNTEGLO, 3 SKYSONA, 1 LYFGENIA; full-year guidance 85-105 starts.
- First LYFGENIA patient start completed; revenue expected in Q3 2024.
- Cash $264M (incl. $52M restricted); expects runway through Q1 2026 assuming $50M additional loan tranches.
- Restating 2022 and 2023 financials for lease accounting; no impact on cash or revenue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1293971/000129397124000020/0001293971-24-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1293971/000129397124000020/blue-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001293971-24-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer